Acute

14 registered clinical trials studyying Acute — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant NCT07123662	Guangzhou Bio-gene Technology Co., Ltd	EARLY_Phase 1
Not Yet Recruiting	In This Study, we Are Testing Whether Combining Two Interventions, in the Early Stages of Tinnitus, is More Ef NCT07128004	Newcastle University	N/A
Completed	Infusion of Dexmedetomidine Versus Lidocaine in Management of Acute Postoperative Pain After Modified Radical NCT06974656	Cairo University	N/A
Not Yet Recruiting	Prediction of Acute Pancreatitis Outcome NCT06653205	Assiut University	—
Recruiting	Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome NCT05673057	Molecular Partners AG	Phase 1 / Phase 2
Unknown	Electroacupuncture on Modifying Inflammatory Levels of Cytokines and Metabolites in Stroke Patients. NCT05734976	China Medical University Hospital	N/A
Unknown	Predictive Value of Human Microbiome and Serological Markers for Clinical Outcome of Cerebral Hemorrhage NCT05551923	Nanfang Hospital, Southern Medical University	—
Completed	Hemodynamic Response and Motor Functions Following Transcranial Direct Current Stimulation in Acute Stroke NCT04051658	Mahidol University	N/A
Completed	Pre-oxygenation With High-flow Nasal Cannula in Adults During Rapid Sequence Induction Anesthesia NCT03516175	Karolinska University Hospital	N/A
Completed	Interfascial Infiltration for Acute Unspecific Low Back Pain in the Emergency Department NCT03968185	University Hospital, Montpellier	—
Unknown	Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis NCT01227863	Azidus Brasil	Phase 3
Unknown	Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Bacterial Pneumonia NCT01152424	Seoul National University Bundang Hospital	—
Completed	Soluble Triggering Receptor Expressed on Myeloid Cells in Severe Acute Pancreatitis NCT01193413	Changhai Hospital	—
Completed	Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML NCT00502385	AstraZeneca	Phase 1